Hot AI Targets
We leverage our proprietary AI platform to mine precision targets with high druggability from massive, heterogeneous multi-omics datasets. Rather than presenting an exhaustive, unfiltered list of public database targets, our portfolio focuses exclusively on high-value, AI-screened nodes. Every target in our navigator integrates advanced computational simulation predictions with preliminary wet-lab validation, establishing a new standard for biological relevance and technical feasibility.
Fig.1 Target identification and drug development in the age of artificial intelligence.1
BEYOND LITERATURE REVIEWS: AI-DEEP-SCREENED PRECISION TARGETS
Discover How We Can Help - Request a Consultation!
Core Value Proposition
Modern biopharmaceutical development stands at a critical juncture. Traditional empirical discovery frameworks rely heavily on legacy physical compound libraries and high-throughput screening (HTS). These approaches are increasingly limited by staggering development timelines (10–15 years), massive capital requirements (averaging $2.6 billion per approved asset), and clinical attrition rates exceeding 90%. Most of these failures are attributable to poor initial target validation, unexpected off-target toxicities, and the rapid emergence of resistance through compensatory signaling pathways.
At Creative Biolabs, we bypass the limitations of legacy physical pipelines by deploying a self-improving, autonomous discovery architecture designed to navigate high-dimensional chemical and biological spaces. Our platform is engineered around three foundational pillars that redefine target discovery:
Dynamic Multi-Omics Integration
By updating our database with real-world biological data, we bypass historical dataset biases and use network-based deep learning to identify novel disease dependencies and synthetic lethality in real time.
Conquering "Undruggable" Targets
We use 3D spatial reasoning, co-folding prediction, and diffusion models to map transient conformational states and cryptic pockets, enabling therapeutic optimization against targets lacking classic static binding sites.
Multi-Objective Optimization
To prevent pathway escape and drug resistance, our generative models use multi-objective Reinforcement Learning (RL) to co-optimize candidates for affinity, tissue specificity, and safety, embedding developability directly into de novo generation.
Interactive Hot-Target Navigator
1. Oncology
Our oncology platform leverages advanced deep generative modeling to target highly complex protein-protein interfaces (PPIs) and dynamic intracellular enzymes, enabling the de novo design of multi-specific biotherapeutics and antibody-drug conjugates (ADCs) that minimize pathway escape.
| ALK | BCL6 | BRAF |
| BTK | CD40 | CDK12/13 |
| c-Met | CXCL13 | EGFRvIII |
| GPC3 | GPR52 | HER2 |
| Intracellular Targets | IRAK4 | KRAS |
| LAG-3 | MEN1 | NTRK |
| OX-40 and 4-1BB | PD-1&VEGF | PI3Kα |
| ROS1 | STAT6 | TBK1 |
| TIGIT | TL1A | TNIK |
| Tumor-Associated Carbohydrate Antigens | USP1 | WRN helicase |
| YAP/TAZ-TEAD PPI |
2. Neurodegenerative Diseases
By combining 3D structural simulations with highly predictive physiological modeling, our platform excels at predicting blood-brain barrier (BBB) permeability and identifying small molecules or specialized biologics that inhibit toxic protein misfolding or enhance neuro-immune clearance.
| Alpha-synuclein (α-syn) | Amyloid beta (Aβ) | IGF1R |
| LRRK2 | Tau | TREM2 |
3. Autoimmune Diseases
We achieve highly precise therapeutic targeting in autoimmune diseases by modeling complex receptor-ligand kinetics and immune cell microenvironments, facilitating the discovery of selective inhibitors and multi-specific antibodies that modulate specific inflammatory pathways without causing broad immunosuppression.
| BAFF and APRIL | BTK | CD19 |
| CD38 | FcγRIIb | IL-17A and IL-17F |
| IRAK4 | STAT6 | TYK2 |
4. Infectious Diseases
Our generative AI engines adapt dynamically to rapid pathogen evolution, predicting viral mutational landscapes to rapidly design broad-spectrum neutralizing agents, vaccine antigens, and small-molecule inhibitors targeted at conserved structural regions.
| HIV GP140 | SARS-CoV-2 spike protein |
Modular Categorization
Can't find the target you're interested in? Our platform enables the rapid creation of customized screening pipelines based on protein structures.
The molecular universe is far too vast to be captured by a pre-compiled target list. If your specific target of interest is not listed in our navigator, Creative Biolabs provides fully customizable, end-to-end computational pipeline creation. By inputting primary amino acid sequences or raw structural data, our platform can autonomously execute:
- De novo binding pocket identification and structural druggability assessments.
- Generative molecular design incorporating real-world synthetic feasibility filters (e.g., automated retrosynthesis routing).
- Active learning-driven property prediction tailored specifically to your project's unique target profile and safety requirements.
This scalable infrastructure ensures that regardless of target complexity or lack of historical literature, we can establish a high-affinity, developable lead discovery program tailored directly to your pipeline requirements.
Discover How We Can Help - Request a Consultation!
Frequently Asked Questions
Q: How does Creative Biolabs ensure the synthetic feasibility of AI-generated molecular candidates?
A: We eliminate "synthetic infeasibility" by embedding reaction-based constraints and retrosynthetic planning engines directly into our generative loop. Every generated molecular candidate is scored and filtered for real-world synthetic accessibility, starting materials availability, and reaction yield prior to moving to laboratory validation.
Q: How does the platform address data scarcity and historical target bias?
A: Public databases heavily favor well-studied, legacy protein families. We overcome this bias using Active Learning (AL) driven by uncertainty and diversity sampling. Our platform flags high-uncertainty areas in the chemical-target space for prioritized testing, using the resulting wet-lab feedback to dynamically refine and update our property predictors for novel or low-data targets.
Q: What computational models underpin your structural target predictions?
A: Our structural predictive engine integrates advanced co-folding algorithms, graph neural networks (GNNs), and 3D diffusion models. Instead of relying on static 2D SMILES strings, we evaluate full 3D spatial conformations to model steric effects, shape complementarity, and structural flexibility critical for high-affinity binding to complex biological interfaces.
Q: How does Creative Biolabs' multi-target (polypharmacology) design differ from conventional single-target approaches?
A: To prevent drug resistance and compensatory pathway escape in complex diseases, we employ multi-objective Reinforcement Learning (RL). Using composite reward functions, our AI balances conflicting pharmacological goals in a single molecule—such as optimizing simultaneous affinity for two distinct therapeutic targets while avoiding interactions that trigger cardiotoxicity or hepatotoxicity.
Q: How do we transition from computational "in silico" results to laboratory validation?
A: We bridge computational design and physical validation through an integrated wet-lab pipeline. Once the platform identifies high-scoring, synthetically feasible candidates, we initiate high-throughput expression, purification, and assay screening. This closed-loop approach feeds biological data directly back into our active learning models to continuously improve computational accuracy.
Get the Latest Industry Research Reports
AI integration in target discovery is now a clinical necessity to bypass the high costs and attrition rates of legacy frameworks. By pairing deep generative modeling with multi-objective reinforcement learning and robust synthetic validation, Creative Biolabs provides an integrated path from target identification to lead optimization. Whether targeting oncology, GPCRs, neurodegeneration, or custom nodes, our computational suites deliver high-affinity, biochemically validated leads. To schedule a technical consultation with our scientific team, discuss custom target pipeline integration, or request detailed platform validation data, please reach out to us.
Reference
- Fleming, Payton, and Andrey A. Ivanov. "Target discovery and drug design in the era of artificial intelligence." Medicinal Chemistry Research (2026): 1-31. under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1007/s00044-026-03562-1.